Zealand Pharma A/S (OCSE:ZEAL) Change In Receivables : kr0.0 Mil (TTM As of Dec. 2023)

View and export this data going back to 2010. Start your Free Trial

What is Zealand Pharma A/S Change In Receivables?

Zealand Pharma A/S's change in receivables for the quarter that ended in Dec. 2023 was kr0.0 Mil. It means Zealand Pharma A/S's Accounts Receivable stayed the same from Sep. 2023 to Dec. 2023 .

Zealand Pharma A/S's change in receivables for the fiscal year that ended in Dec. 2023 was kr-18.6 Mil. It means Zealand Pharma A/S's Accounts Receivable increased by kr18.6 Mil from Dec. 2022 to Dec. 2023 .

Zealand Pharma A/S's Accounts Receivable for the quarter that ended in Dec. 2023 was kr122.4 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Zealand Pharma A/S's Days Sales Outstanding for the three months ended in Dec. 2023 was 480.54.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Zealand Pharma A/S's liquidation value for the three months ended in Dec. 2023 was kr1,341.6 Mil.

Zealand Pharma A/S Change In Receivables Historical Data

The historical data trend for Zealand Pharma A/S's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zealand Pharma A/S Change In Receivables Chart

Zealand Pharma A/S Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Receivables

Get a 7-Day Free Trial

-21.06

-7.72

-64.49

33.11

-18.61

Zealand Pharma A/S Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Change In Receivables	Get a 7-Day Free Trial															-	-	-	-	-

Zealand Pharma A/S Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was kr0.0 Mil.

Zealand Pharma A/S (OCSE:ZEAL) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Zealand Pharma A/S's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	122.359	/	23.235	*	91
=	480.54

2. In Ben Graham's calculation of liquidation value, Zealand Pharma A/S's accounts receivable are only considered to be worth 75% of book value:

Zealand Pharma A/S's liquidation value for the quarter that ended in Dec. 2023 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	1633.057	-	387.154	+	0.75 * 122.359	+	0.5 * 7.935
=	1,341.6

Zealand Pharma A/S Change In Receivables Related Terms

Thank you for viewing the detailed overview of Zealand Pharma A/S's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Zealand Pharma A/S (OCSE:ZEAL) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zealand Pharma A/S (OCSE:ZEAL) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

ZLDPF:USA ZEALc:UK 0NZU:UK 22Z:Germany

Address

Sydmarken 11, Soborg, DNK, DK-2860

Website

https://www.zealandpharma.com

Zealand Pharma A/S is a biotechnology company. It is focused on the discovery, design, and development of peptide-based medicines. The company's product pipeline includes three product candidates in clinical development: glepaglutide, which is being developed to treat short bowel syndrome or SBS; dasiglucagon formulated for use in a dual-hormone artificial pancreas system for diabetes management; and dasiglucagon for use in the treatment of congenital hyperinsulinism. The company has out-licensed a peptide program to Boehringer Ingelheim that has been moved ahead into early clinical development: a once-weekly novel dual-acting GLP-1/glucagon agonist for the treatment of obesity and/or Type 2 diabetes.